Type 2 Diabetes, Renal Impairment, and CHD: Reducing 2 Vascular Risks With 1 Stone

Panelists

Case Study: 58-Year-Old Male

Incidence of MI in Subjects With T2DM vs the Nondiabetic CAD Population

Is Type 2 Diabetes a Coronary Risk Equivalent?

Risk for Cardiovascular Events Is Greatest When Both Diabetes and CKD Are Present

Mortality Risk Doubles in Comorbid T2DM and CKD*

All-Cause and Cardiovascular Mortality by eGFR in Subjects With and Without Diabetes

All-Cause Mortality by eGFR in Subjects With and Without Diabetes and Hypertension

Effect of Intensive Glucose Control on Major Cardiovascular Events

Effect of Intensive Glucose Control on All-Cause Mortality

Effect of Intensive Glucose Control on Major CV Events by History of Macrovascular Disease

PPAR-a and PPAR-g Agonists: Target Systems

TZDs: Renal Function in Patients With Baseline Normo- and/or Microalbuminuria and T2DM

CV Events With PPAR-g Agonists

PROactive: Effect of Pioglitazone on CV Outcomes in T2DM Patients by CKD Status

VA-HIT: Effect of Gemfibrozil on Cardiac Events in Secondary Prevention

VA-HIT: Effect of Gemfibrozil on CV Events and Death in Patients With CRI

FIELD: Long-Term Effect of Fenofibrate on Albuminuria in T2DM

ACCORD Lipid: Effect of Statin Plus Fenofibrate vs Statin Alone on Markers of Renal Function

ACCORD Renal Ancillary Study: Reversibility of Fenofibrate-Related Renal Function Impairment

Fenofibrate Treatment in Type 2 Diabetes: Effect on Renal Function

Effects of Fibrates on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis

Fibrates: Is High TG, Low HDL-C the Optimal Patient Type?

Dual PPAR-a/g Agonists

Targets of Glucose-Lowering Drugs

Impact of Intensive Glycemic Control in Subjects With CKD: Micro- and Macroalbuminuria

Impact of Intensive Glycemic Control in Subjects With CKD: Serum Creatinine

Impact of Intensive Glycemic Control in Subjects With CKD: All-Cause and CV Mortality

Impact of Intensive Glycemic Control in Subjects With CKD: End-Stage Renal Disease

NKF Diabetes and CKD Systematic Review Conclusions

STENO-2: Multifactorial Risk Factor Management in Type 2 Diabetes

STENO-2: All-Cause Mortality

Dual a/g PPAR Agonist: Effect of Muraglitazar on A1c and Lipid Levels

Muraglitazar Clinical Development

Effect of Muraglitazar on All-Cause Mortality and MACE in Patients With T2DM

GALLANT 8: Effect of Tesaglitazar on Top of Metformin vs Metformin Alone on A1c

GLAD: Effect of Tesaglitazar vs Pioglitazone on Lipid Measures

Effect of Tesaglitazar on Serum Creatinine and Glomerular Filtration

Tesaglitazar Clinical Development

SYNCHRONY: Effect of Aleglitazar vs Pioglitazone on LDL-C and HDL-C

SYNCHRONY: Effect of Aleglitazar vs Pioglitazone on A1c and FPG

SYNCHRONY: Effect of Aleglitazar on Markers of Renal Function

SESTA R: Impact of Supratherapeutic Doses of Aleglitazar on Renal Function in T2DM

ALENEPHRO: Aleglitazar Phase 2 Renal Function Study

ALENEPHRO: Preliminary Details

Expected Targets for Dual PPAR-a/g Agonists

Effect of Aleglitazar on Cardiometabolic Risk

ALECARDIO: Aleglitazar in Patients With T2DM and ACS

Blood Glucose-Lowering Agents and Cardiovascular Risk Management

Program Summary